Market Newsdesk

CUPERTINO, Calif., Jan. 5, 2021 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced the appointment of two new members to its board of directors, Gail J. Maderis, MBA and Mohammad Azab, M.D., M. Sc., MBA, two senior industry veterans with extensive drug development, clinical research and medical affairs experience.

“We are pleased to welcome Ms. Maderis and Dr. Azab to our board as we continue to enhance our board in line with our maturing company,” stated James E. Brown, D.V.M., President and Chief Executive Officer of DURECT. “Their extensive expertise will be valuable as we continue to advance our clinical pipeline and create value for our shareholders, in particular as we advance the Phase 2b AHFIRM study of our lead candidate DUR-928 for the treatment of alcohol-associated hepatitis (AH) and plan for other indications with DUR-928.”

Ms. Maderis stated, “Clinical data from DURECT’s lead clinical asset DUR-928 in AH and non-alcoholic steatohepatitis (NASH) look very promising and show the potential of DUR-928 for the treatment of multiple organ injury and chronic liver diseases. I am eager to work with the DURECT board and management team to bring additional perspective as the company advances its clinical pipeline and explores additional opportunities for DUR-928 to fulfill unmet needs.”

Dr. Azab added, “I am excited to be joining the DURECT board as the company advances DUR-928 in the AHFIRM trial and gets closer to potentially offering a life-saving therapy to people affected by this life-threating condition. I look forward to working with the team and providing guidance as DURECT continues to advance DUR-928 through development and eventually, to potential approval and commercialization.”

Gail Maderis has served as President and CEO of Antiva Biosciences, a venture funded biopharma company developing topical therapies to treat the pre-cancerous lesions caused by HPV, since 2015.  From 2009 to 2015, she led BayBio, the industry organization representing and supporting Northern California’s life science community. From 2003 to 2009, she served as President and CEO of Five Prime Therapeutics, Inc., a protein discovery and development company. Prior to FivePrime, Ms. Maderis held senior executive positions at Genzyme Corporation, including founder and president of Genzyme Molecular Oncology. She also practiced management and strategy consulting with Bain & Co. She serves on the corporate boards of Allarity Therapeutics and Valitor, Inc., as well as on the non-profit boards of BIO (Emerging Company and Health Sections), CLSI, The Termeer Foundation and the University of California Berkeley Foundation Board of Trustees. She received a BS in business from UC Berkeley and an MBA from Harvard Business School.

Dr. Mohammad Azab served as President and Chief Medical Officer of Astex Pharmaceuticals, Inc. since 2014 after holding the position of Chief Medical Officer there since 2009.  As of November 2020, upon retirement from his management role, Dr. Azab has served as the Chair of the Board of Directors for Astex Pharmaceuticals, Inc, which is a wholly owned subsidiary of Otsuka Pharmaceuticals, focused on the discovery and development of drugs in oncology and other therapeutic areas. Previously, Dr. Azab served as President and CEO of Intradigm Corporation, a developer of siRNA cancer therapeutics. Prior to this, Dr. Azab served as Executive Vice President of Research and Development, and Chief Medical Officer of QLT Inc., and in several drug development leadership positions at Astra Zeneca in the United Kingdom and Sanofi Pharmaceuticals in France. During his carrier he has led or has been involved with the development of 8 approved drugs, 7 in Oncology and one in Ophthalmology.  Dr. Azab holds his medical degree (MB ChB) from Cairo University and an M.B.A. from the Richard Ivey School of Business, University of Western Ontario. He received post-graduate training and degrees in oncology research from the University of Paris-Sud and biostatistics from the University of Pierre et Marie Curie in Paris, France. Dr. Azab has more than 30 years of experience in clinical research, global drug development, and business management and led the global development of several drugs currently approved in oncology and other therapeutic areas. Currently, he also serves on the board of directors of Xenon Pharmaceuticals Inc. 

About DURECT Corporation
DURECT is a biopharmaceutical company committed to transforming the treatment of acute organ injury and chronic liver diseases by advancing novel and potentially lifesaving therapies based on its endogenous epigenetic regulator program. DUR-928, the company’s lead drug candidate is in clinical development for the potential treatment of alcohol-associated hepatitis (AH) for which FDA has granted a Fast Track Designation, COVID-19 patients with acute liver or kidney injury, and non-alcoholic steatohepatitis (NASH). DURECT’s proprietary drug delivery technologies are designed to enable new indications and enhanced attributes for small-molecule and biologic drugs. One late-stage product candidate in this category is POSIMIR® (bupivacaine sustained-release solution), an investigational locally-acting, non-opioid analgesic intended to provide up to three days of continuous pain relief after surgery. For more information about DURECT, please visit www.durect.com and follow us on Twitter https://twitter.com/DURECTCorp.

DURECT Forward-Looking Statement
The statements in this press release regarding clinical development plans for DUR-928, including the potential use of DUR-928 to treat AH and other acute organ injuries, including in COVID-19 patients, as well as chronic liver diseases, such as NASH, and the potential use of POSIMIR to provide pain relief after surgery are forward-looking statements involving risks and uncertainties that can cause actual results to differ materially from those in such forward-looking statements. Potential risks and uncertainties include, but are not limited to, the risks that the start of the AHFIRM trial or other trials will be delayed due to COVID-19 or other factors, that the AHFIRM trial will take longer than expected and may not replicate results from earlier trials, that the clinical trial of DUR-928 in COVID-19 patients is delayed or stopped because of changes to the standard of care, the availability of alternative therapies, required protocol changes or lack of available patients, the risk that clinical trials of DUR-928 do not demonstrate the safety or efficacy of DUR-928 in a statistically significant manner, the risk that the FDA will not approve POSIMIR or approve POSIMIR with a limited label, the risk that additional time and resources may be required for development, testing and regulatory approval of DUR-928 or the Company’s other product candidates, potential adverse effects arising from the testing or use of our drug candidates, our potential failure to maintain our collaborative agreements with third parties and risks related to our ability to obtain capital to fund operations and expenses. Further information regarding these and other risks is included in DURECT’s Form 10-Q filed on November 3, 2020 under the heading “Risk Factors.”

NOTE: POSIMIR® and SABER® are trademarks of DURECT Corporation.  Other referenced trademarks belong to their respective owners.  DUR-928 and POSIMIR are investigational drug candidates under development and have not been approved for commercialization by the U.S. Food and Drug Administration or other health authorities for any indication.

 

View original content:http://www.prnewswire.com/news-releases/durect-corporation-appoints-two-new-board-members-301200829.html

SOURCE DURECT Corporation

NAPLES, Fla., Jan. 5, 2021 /PRNewswire/ — Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a patient-first biotechnology company developing novel cannabinoid medicines to improve quality of life for cancer patients, announced today that it has appointed Marcus Schabacker, M.D., Ph.D., to the Company’s Board of Directors.

“Dr. Schabacker’s significant medical, corporate and board experience over the years make him a perfect fit to join Enveric at this pivotal moment for our Company,” said David Johnson, Chairman and CEO, Enveric Biosciences. “Providing the best and safest patient care has always been at the forefront of Dr. Schabacker’s work – aligning squarely with Enveric’s mission – and we look forward to leveraging his knowledge and insights as we continue our research and develop natural compounds, including cannabinoids, to provide treatments for unmet medical needs.”

With more than 35 years of healthcare experience, Dr. Schabacker currently serves as President and CEO at the ECRI Institute, a nonprofit organization focused on advancing effective, evidence-based healthcare globally. Prior to joining ECRI, Dr. Schabacker worked at Baxter Healthcare Corporation, serving in various roles including Corporate Vice President and Chief Scientific Officer; Chairman of the Executive Quality Council; Chief Scientific Officer, Medical Products; and Vice President, R&D, Medical Products.

For over a decade, Dr. Schabacker has served on numerous boards of both small- and mid-sized companies, providing organizations with strategic guidance for accelerating growth and building successful, sustainable management teams. He is also a board-certified anesthesiologist and intensive care specialist.

“Over the course of my career, and still to this day, patients’ needs remain my top priority,” added Dr. Schabacker. “The team at Enveric Biosciences lives by this principle, as well, which is why I could not pass up the opportunity to join its Board of Directors. As the Company advances its pipeline of innovative, naturally occurring compounds in partnership with leading clinics, I look forward to working closely with Enveric to help bring these treatments to patients in need, especially those suffering from cancer treatments’ debilitating side effects.”

About Enveric Biosciences
Enveric Biosciences is a patient-first biotechnology company developing rigorously tested, novel cannabinoid medicines to improve quality of life for cancer patients. Initial indications include radiodermatitis, a common and often severe side effect of radiation therapy, and chemotherapy-induced neuropathy. For more information, please visit https://www.enveric.com/.

Forward-Looking Statements
This press release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. These statements relate to future events or future performance. All statements other than statements of historical fact may be forward-looking statements or information. Generally, forward-looking statements and information may be identified by the use of forward-looking terminology such as “plans”, ” expects” or “does not expect”, “proposed”, “is expected”, “budgets”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases, or by the use of words or phrases which state that certain actions, events or results may, could, would, or might occur or be achieved. Forward-looking statements consist of statements that are not purely historical, including any statements regarding beliefs, plans, expectations or intentions regarding the future. Readers are cautioned not to place undue reliance on forward-looking statements, as there can be no assurance that the Amalgamation will be consummated or that the parties other plans, intentions or expectations upon which they are based will occur. By their nature, forward-looking statements involve numerous assumptions, known and unknown risks and uncertainties, both general and specific that contribute to the possibility that the predictions, estimates, forecasts, projections and other forward-looking statements will not occur.

The forward-looking statements contained in this press release are made as of the date of this press release. Except as required by law, the Company disclaims any intention and assumes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Additionally, the Company undertakes no obligation to comment on the expectations of, or statements made by, third parties in respect of the matters discussed above.

Investor Contacts

Valter Pinto / Allison Soss
KCSA Strategic Communications
212.896.1254 / 212.896.1267
[email protected] 

Media Contacts

Caitlin Kasunich / Raquel Cona
KCSA Strategic Communications
212.896.1241 / 516.779.2630
[email protected] 

 

View original content:http://www.prnewswire.com/news-releases/enveric-biosciences-appoints-dr-marcus-schabacker-to-board-of-directors-301200834.html

SOURCE Enveric Biosciences

SAN JOSE, Calif., Jan. 5, 2021 /PRNewswire/ — Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced today that Dr. Amit Kumar, Anixa’s Chief Executive Officer, will present at the virtual H.C. Wainwright BioConnect 2021 Conference being held January 11-14, 2021. 

During the presentation, Dr. Kumar will provide an overview of Anixa’s business and highlight recent corporate achievements, including the authorization by the U.S. Food and Drug Administration to commence human clinical trials of its prophylactic breast cancer vaccine, as well as anticipated milestones in its Covid-19 and CAR-T based ovarian cancer therapeutic programs. 

Details of Anixa’s presentation are as follows:

Event:               H.C. Wainwright BioConnect 2021 Conference

Date & Time:   On demand, beginning 6:00 a.m. ET, Monday, January 11, 2021

Webcast link:  https://journey.ct.events/view/bb8d6921-4e38-48d8-a4b1-da6611e7560b

An archive of the webcast will remain available for 90 days after the event.

About Anixa Biosciences, Inc.
Anixa is a publicly-traded biotechnology company developing a number of programs addressing cancer and infectious disease.  Anixa’s therapeutics portfolio includes a cancer immunotherapy program which uses a novel type of CAR-T, known as chimeric endocrine receptor T-cell (CER-T) technology, and a Covid-19 therapeutics program focused on inhibiting certain viral protein function.  The company’s vaccine portfolio includes a vaccine to prevent breast cancer, and specifically triple negative breast cancer (TNBC), the most deadly form of the disease, and a vaccine to prevent ovarian cancer.  These vaccine technologies focus on immunizing against specific proteins that have been found to be expressed in certain forms of cancer.  Anixa continually examines emerging technologies in complementary fields for further development and commercialization.  Additional information is available at www.anixa.com.

Forward-Looking Statements:
  Statements that are not historical fact may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.  Forward-looking statements are not statements of historical facts, but rather reflect Anixa’s current expectations concerning future events and results.  We generally use the words “believes,” “expects,” “intends,” “plans,” “anticipates,” “likely,” “will” and similar expressions to identify forward-looking statements.  Such forward-looking statements, including those concerning our expectations, involve risks, uncertainties and other factors, some of which are beyond our control, which may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements.  These risks, uncertainties and factors include, but are not limited to, those factors set forth in “Item 1A – Risk Factors” and other sections of our most recent Annual Report on Form 10-K as well as in our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K.  We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.  You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented in this press release.

Investor contact:
Mike Catelani
[email protected] 
408-708-9808

Media contact:
Sherry Ash
[email protected]

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/anixa-biosciences-to-present-at-the-hc-wainwright-bioconnect-2021-conference-301200871.html

SOURCE Anixa Biosciences, Inc.

FOOTHILL RANCH, Calif., Jan. 5, 2021 /PRNewswire/ — BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, announced today that Todd Norbe, President and Chief Executive Officer and John Beaver, Chief Operating Officer and Chief Financial Officer, will be providing an overview of the Company, as well as recent progress and achievements, at the H.C. Wainwright BIOCONNECT 2021 Investor Conference, which takes place January 11-14, 2021. A webcast of BIOLASE’s recorded company presentation will be available on-demand beginning at 6:00 a.m. ET on January 11^th, and can be accessed in the investor relations section of BIOLASE’s website at www.biolase.com.

Management will also be available for virtual one-on-one meetings with investors during the event. To request a meeting please contact your H.C. Wainwright representative or BIOLASE’s investor relations firm at [email protected]. 

About BIOLASE, Inc.

BIOLASE is a medical device company that develops, manufactures, markets, and sells laser systems in dentistry and medicine.  BIOLASE’s products advance the practice of dentistry and medicine for patients and healthcare professionals.  BIOLASE’s proprietary laser products incorporate approximately 261 patented and 52 patent-pending technologies designed to provide biologically and clinically superior performance with less pain and faster recovery times.  BIOLASE’s innovative products provide cutting-edge technology at competitive prices to deliver superior results for dentists and patients.  BIOLASE’s principal products are revolutionary dental laser systems that perform a broad range of dental procedures, including cosmetic and complex surgical applications.  BIOLASE has sold over 41,200 laser systems to date in over 80 countries around the world.  Laser products under development address BIOLASE’s core dental market and other adjacent medical and consumer applications.

For updates and information on Waterlase iPlus®, Waterlase Express™, and laser dentistry, find BIOLASE online at www.biolase.com, Facebook at www.facebook.com/biolase, Twitter at www.twitter.com/biolaseinc, Instagram at www.instagram.com/waterlase_laserdentistry, and LinkedIn at www.linkedin.com/company/biolase.

BIOLASE®, Waterlase® and Waterlase iPlus® are registered trademarks of BIOLASE, Inc.

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/biolase-to-present-at-the-hc-wainwrights-bioconnect-2021-investor-conference-301200830.html

SOURCE BIOLASE, Inc.

As a PlantX partner, Else will expand product distribution, drive global awareness and sales via all Plant X channels, digital and physical locations.

VANCOUVER, BC, Jan. 5, 2021 /PRNewswire/ – ELSE NUTRITION HOLDINGS INC. (TSXV: BABY) (OTCQX: BABYF) (FSE: 0YL) (“Else” or the “Company”) the Plant-Based baby, toddler and children nutrition company, is pleased to announce that it is will be listed on Plant X, the digital face of the Plant-Based community and one-stop-shop for plant-based products, as the first product available for order in the newly created baby products section of Plant X’s ecommerce platform (www.PlantX.ca/baby).

“We’re thrilled to be listed on the Plant X platform, and there’s a real need for such a community. Joining this innovative online platform solely dedicated to Plant-Based companies, aligns perfectly with our mission to bring real clean label, whole, sustainable, Plant-Based options for parents to nourish their children,” said Hamutal Yitzhak, CEO and Co-Founder of Else Nutrition. “We’re proud to be part of platform of like-minded, purpose-driven brands and raising awareness for Plant-Based Nutrition and its benefits to a growing segment of consumers. This will help bolster our presence in both North America and Europe,” she added.

“Launching the new baby products section of PlantX.com with Else Nutrition is very exciting for us,” said Julia Frank, Plant X CEO. “We’ve seen the success of the baby formula vertical and having it in our Plant-Based umbrella only adds to the potential in this space.”

Plant X is now a publicly traded company in the U.S., Canada and Germany with brick and mortar locations on the way in North America and Tel Aviv, Israel.

About PlantX Life Inc.

As the digital face of the Plant-Based community, Plant X’s platform is the one-stop-shop for everything Plant-Based. With its fast-growing category verticals, the Company offers customers across North America more than 10,000 Plant-Based products. In addition to offering meal and indoor plant deliveries, the Company currently has plans underway to expand its product lines to include cosmetics, clothing, and its own water brand — but the business is not limited to an e-commerce platform. The Company uses its digital platform to build a community of like-minded consumers, and most importantly, provide education. Its successful enterprise is being built and fortified on partnerships with top nutritionists, chefs, and brands. The Company eliminates the barriers to entry for anyone interested in living a Plant-Based lifestyle, and thriving in a longer, healthier, and happier life.

About Else Nutrition Holdings Inc.

Else Nutrition GH Ltd. is an Israel-based food and nutrition company focused on developing innovative, clean and plant-based food and nutrition products for infants, toddlers, children, and adults. Its revolutionary, plant-based, non-soy, formula is a clean-ingredient alternative to dairy-based formula. Else Nutrition (formerly INDI) won the “2017 Best Health and Diet Solutions” award at the Global Food Innovation Summit in Milan. Else Plant-Based Toddler Nutrition was a 2020 Top-seller on Amazon, in the New Product within Baby & Toddler Formula Category. The holding company, Else Nutrition Holdings Inc., is a publicly traded company, listed as TSX Venture Exchange under the trading symbol BABY and is quoted on the US OTC Markets QX board under the trading symbol BABYF and on the Frankfurt Exchange under the symbol 0YL. Else’s Executives includes leaders hailing from leading infant nutrition companies. Many of Else advisory board  members had past executive roles in companies such as Mead Johnson, Abbott Nutrition, Plum Organics and leading infant nutrition Societies,  and some of them currently serve in different roles in leading medical centers and academic institutes such as Boston Children’s Hospital, Pediatrics at Harvard Medical School, USA, Children’s Hospital of Colorado, Tel Aviv University, Schneider Children’s Medical Center of Israel, Rambam Medical Center and Technion, Israel and University Hospital Brussels, Belgium.

For more information, visit: elsenutrition.com or @elsenutrition on Facebook and Instagram.

TSX Venture Exchange

Neither the TSX Venture Exchange nor its regulation services provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Caution Regarding Forward-Looking Statements

This press release contains statements that may constitute “forward-looking statements” within the meaning of applicable securities legislation. Forward-looking statements are typically identified by words such as “will” or similar expressions. Forward-looking statements in this press release include statements with respect to the anticipated dates for filing the Company’s financial disclosure documents.  Such forward-looking statements reflect current estimates, beliefs and assumptions, which are based on management’s perception of current conditions and expected future developments, as well as other factors management believes are appropriate in the circumstances. No assurance can be given that the foregoing will prove to be correct. Forward-looking statements made in this press release assume, among others, the expectation that there will be no interruptions or supply chain failures as a result of COVID 19 and that the manufacturing, broker and supply logistic agreement with the Company do not terminate.  Actual results may differ from the estimates, beliefs and assumptions expressed or implied in the forward-looking statements.  Readers are cautioned not to place undue reliance on any forward-looking statements, which reflect management’s expectations only as of the date of this press release. The Company disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

View original content to download multimedia:http://www.prnewswire.com/news-releases/else-expands-north-american-retail-presence-as-first-baby-category-product-on-plant-x–a-leading-plant-based-ecommerce-and-digital-community-301200577.html

SOURCE Else Nutrition Holdings Inc.

LOVELAND, Colo., Jan. 5, 2021 /PRNewswire/ — Heska Corporation (NASDAQ: HSKA – News; “Heska” or the “Company”), a leading global provider of advanced veterinary diagnostic and specialty products, announced that Kevin Wilson, Heska’s President & Chief Executive Officer, will present at the 39^th Annual J.P. Morgan Healthcare Conference on Wednesday January 13, 2021 at 2 p.m. Eastern Time.

Mr. Wilson’s presentation will be available to registered conference attendees in a live video format via the conference website.  A live audio-only version of the presentation and question and answer session will be available to non-registered attendees at Heska Audio-Only J.P. Morgan Conference Presentation. The webcast and presentation will be archived on Heska’s website shortly after the event and a replay will be available for 90 days following the conference.

Mr. Wilson and members of Heska management will also be participating in one-on-one meetings on January 13^th. To request a meeting, please contact J.P. Morgan at 1×[email protected] or Heska Investor Relations at [email protected].

For more information regarding the J.P. Morgan 2020 Healthcare Conference, visit: J.P. Morgan Healthcare Conference Website.

About Heska

Heska Corporation (NASDAQ: HSKA) manufactures, develops and sells advanced veterinary diagnostic and specialty healthcare products through its two business segments: North America and International. Both segments include Point of Care Lab testing instruments and consumables, digital imaging products, software and services, data services, allergy testing and immunotherapy, and single-use offerings such as in-clinic diagnostic tests and heartworm preventive products. The North America segment also includes private label vaccine and pharmaceutical production under third-party agreements and channels, primarily for herd animal health.

                                                                                                           

View original content to download multimedia:http://www.prnewswire.com/news-releases/heska-to-present-at-upcoming-jp-morgan-annual-healthcare-conference-301200833.html

SOURCE Heska Corporation

Strategic Position in BC’s Cariboo Gold District with Flagship FG Gold Project

VANCOUVER, BC, Jan. 5, 2021 /PRNewswire/ – KORE Mining Ltd. (TSXV: KORE | OTCQX: KOREF) (“KORE” or the “Company“) is pleased to provide an update on the proposed transfer of all of its British Columbia (“BC“) gold exploration assets (“Spin Out“) into a newly incorporated company called Karus Gold Corp. (“Karus” or “Karus Gold“). 

Updates and Next Steps:

• Spin Out requires approval at the virtual KORE shareholder meeting on January 20, 2021
• Meeting materials filed and mailed in late December 2020
• Shareholders encouraged to vote as soon as possible and no later than January 18, 2021 via the instructions in the materials
• Shareholders may attend the meeting online and will be required to register via the instructions in the materials in advance if they wish to vote online
• Management and the Board of KORE recommends voting in favour of the Spin Out
• Spin Out is supported by Mr. Eric Sprott, KORE’s largest shareholder
• If the Spin Out is approved and final court approval is obtained, KORE shareholders at the distribution date will be eligible to receive Karus shares
• Distribution date expected to be January 22, 2021, subject to change
• Karus shares will not be publicly listed to trade immediately after Spin Out; listing anticipated in the first half of 2021
• Upon completion of the Spin Out, Karus intends to raise capital via a rights offering (“Rights Offering“) to all Karus shareholders
• Rights Offering expected to commence in February 2021, with details to come after closing the Spin Out
• Karus shareholders will have exclusive access to invest in Karus via the Rights Offering, raising initial capital for Karus to execute its strategy

Highlights of Karus Gold:

• Unlocks value of BC assets for KORE shareholders through creation of Karus Gold
• Dominant 1,000 km² land position in the emerging Cariboo Gold District with Osisko Development Corp (TSX:ODV) investing heavily to the north
• Flagship FG Gold project open for growth after 2020 Lower Zone discovery intercepts of:
• 10.0 meters of 3.9 g/t gold at 237 meters downhole
• 14.3 meters of 6.4 g/t gold at 386 meters downhole
• Controls under-explored 110 km trend including five high-priority gold prospects
• Results from 14 FG Gold holes and five Gold Creek holes expected through Q1 2021

Upon completion of the Spin Out, KORE will continue as a leading gold company with a focus on growing and developing the Imperial and Long Valley gold projects in the US.

Scott Trebilcock, KORE’s President & CEO comments, “KORE would like to thank our shareholders for their continued support in 2020 as we unlock value through the spin out process. We believe the value of our BC exploration assets are obscured by the robust economics of our advanced Imperial and Long Valley projects and as such, are looking forward to maximizing shareholder value through the spin out. We expect the Cariboo region in BC will see a major increase in exploration and development in 2021 and beyond.  The spin out of Karus enables KORE shareholders to participate in this exciting and emerging mining district. We encourage our shareholders to vote in favor of the spin out to unlock value from this underappreciated asset.”

Details of the Spin Out are available at www.koremining.com/karus and materials for the special shareholders meeting are available at www.koremining.com/specialmeeting and under KORE’s profile on SEDAR at www.sedar.com.

About KORE’s BC Gold Exploration Assets
KORE controls a dominant 1,000 square kilometers of claims in its South Cariboo Gold District of British Columbia.  The claims host 110 km of structural trend that is highly prospective for gold deposits.  The north part of the Cariboo Gold District is controlled by Osisko Development Corp (TSXV: ODV), which is financing a major exploration and development program that will bring attention to the Cariboo Gold District.  KORE has multiple projects in the Cariboo Gold District, including the FG Gold and Gold Creek gold projects.  Much of the area is under-explored and wide open for additional discoveries.  The Cariboo region is a prolific gold region.  The Cariboo Gold District was host to the Cariboo gold rush in the late 1800’s, followed by a long history of modern gold mining.  The Cariboo region is accessible with local power, a well-developed road network and skilled local labour. 

The FG Gold project hosts an orogenic gold deposit on a 20 km trend defined by gold in soils and geophysics.  Drilling performed by KORE in 2020 transformed the project, opening up the potential for both open pit and underground type mineralization.  The FG Gold project also hosts copper-gold porphyry mineralization at the Nova Zone, discovered by KORE in 2018.  Details of FG Gold Lower Zone discovery including intercepts reported above are detailed in the November 11, 2020 Company news release.

The Gold Creek project is an orogenic gold discovery centered on the “Camp Zone” which show similarities to the high-grade zone of the nearby Spanish Mountain Gold Deposit (TSXV:SPA).  The Camp Zone’s near surface mineralization currently extends over 400 metres along strike and is open along both strike and at depth.  KORE is currently drilling a 2,000-meter program to expand Gold Creek.

In connection with the transaction, the Company and Karus have filed an updated National Instrument 43-101 compliant Technical Report titled “Technical Report on the South Cariboo Property, British Columbia, Canada” effective November 15, 2020 and filed on December 16, 2020, prepared by independent qualified persons Ron Voordouw, P.Geo., Henry Awmack, P. Eng., and Equity Exploration Consultants Ltd (the “Updated Report“).  The Updated Report replaces the previously filed technical report issued to Eureka Resources Inc. in 2015 and amends prior disclosure regarding mineral resources on the FG Gold and Gold Creek gold projects.  The Updated Report is available on the Company’s website at www.koremining.com/Karus and under KORE’s profile on SEDAR at www.sedar.com.

About KORE Mining
KORE is 100% owner of a portfolio of advanced gold exploration and development assets in California and British Columbia.  KORE is supported by strategic investor Eric Sprott who recently invested $7.0 million, bringing his total ownership to 26%.  KORE management and Board are aligned with shareholders, owning an additional 38% of the basic shares outstanding.  KORE is actively developing its Imperial Gold project and is aggressively exploring across its portfolio of assets.

Further information on the Spin Out and KORE can be found on the Company’s website at www.koremining.com/Karus or by contacting us at [email protected] or 888-455-7620.

On behalf of KORE Mining Ltd

“Scott Trebilcock”
Chief Executive Officer

Karus Gold Spin Out Investor Support

David Jan

1-888-455-7620
[email protected]

KORE Investor Relations

Arlen Hansen, KIN Communications
1-888-684-6730
[email protected]  

Technical information with respect to the Cariboo Gold District, FG Gold and the Gold Creek Projects contained in this news release has been reviewed and approved by Michael Tucker, P. Geo. who is KORE’s VP Exploration and is the qualified person under National Instrument 43-101 responsible for the technical matters of this news release.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Cautionary Statement Regarding Forward-Looking Information
This news release contains forward-looking statements relating to the future operations of the Company and Karus Gold and other statements that are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “plan”, “should”, “anticipate”, “expects”, “intends”, “indicates” and similar expressions. All statements other than statements of historical fact, included in this release, including, without limitation, statements regarding the future plans and objectives of the Company and Karus Gold are forward-looking statements.  Forward-looking statements in this news release include, but are not limited to, the expected timeline and date of completion of the Spin Out, the ability of KORE to receive and obtain shareholder approval and court approval, the ability of the parties to satisfy, in a timely manner, the other conditions to closing of the Spin Out, the future listing of Karus Gold and the expected timeline and completion of the anticipated Karus rights offering. There can be no assurance that the Spin Out will be completed or that it will be completed on the terms and conditions contemplated in this news release. The Spin Out could be modified or terminated in accordance with its terms. Such forward-looking statements, and any assumptions upon which they are based, are made in good faith and reflect our current judgment regarding the direction of our business. Management believes that these assumptions are reasonable. Forward-looking information involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information. 

Such factors include, among others: the Spin Out will be completed on the terms currently contemplated, the Spin Out will be completed in accordance with the timing currently expected without any undue delay, all conditions to the completion of the Spin Out will be satisfied or waived in due course and the Spin Out Agreement will not be terminated prior to the completion of the Spin Out, assumptions and expectations related to the trading price of KORE and the future listing of Karus Gold, and other expectations and assumptions concerning the Spin Out. 

In addition to the above summary, additional risks and uncertainties inherent to the Company and its operations are described in the “Risk Factors” section of the Company’s management discussion and analysis for the year ended December 31, 2019, prepared as of April 27, 2020, available under the Company’s issuer profile on www.sedar.com. Other risks and uncertainties include, among other things: the Spin Out may not be completed on the terms, or in accordance with the timing currently contemplated, or at all; the Company and Karus Gold has incurred expenses in connection with the Spin Out and will be required to pay for those expenses regardless of whether or not the Spin Out is completed; the Company and Karus Gold may not be successful in satisfying the conditions to the Spin Out, including failing to obtain KORE shareholder approval; the possibility of adverse reactions or changes in business relationships resulting from the announcement or completion of the Spin Out; the failure to realize the expected benefits of the Spin Out; and other risks inherent to KORE’s current business and/or factors beyond its control which could have a material adverse effect on KORE or the ability to consummate the Spin Out.

Forward-looking statements contained herein are made as of the date of this news release and the Company disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or results, except as may be required by applicable securities laws. There can be no assurance that forward-looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking information. 

View original content to download multimedia:http://www.prnewswire.com/news-releases/kore-mining-provides-update-on-spin-out-of-karus-gold-creating-bc-focused-gold-explorer-301200775.html

SOURCE Kore Mining

SAN RAFAEL, Calif., Jan. 5, 2021 /PRNewswire/ — BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that management will participate in two upcoming virtual conferences.  An audio webcast of the presentations will be available live. You can access the webcast at: https://investors.biomarin.com/. An archived version of the remarks will also be available through the Company’s website for a limited time following the conference.

About BioMarin

BioMarin is a global biotechnology company that develops and commercializes innovative therapies for people with serious and life-threatening rare disorders. The company’s portfolio consists of six commercialized products and multiple clinical and pre-clinical product candidates.  

For additional information, please visit www.biomarin.com. Information on BioMarin’s website is not incorporated by reference into this press release.

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/biomarin-to-participate-in-two-upcoming-virtual-investor-conferences-301200463.html

SOURCE BioMarin Pharmaceutical Inc.

GREENSBORO, N.C., Jan. 5, 2021 /PRNewswire/ — Tanger Factory Outlets Centers, Inc. (NYSE: SKT), a leading operator of upscale open-air outlet centers, today announced the implementation of the executive succession plan initially outlined in April 2020.  As of January 1, 2021, Steven B. Tanger has transitioned to Executive Chair of the Company’s Board of Directors, effective through January 1, 2024 and Stephen Yalof has assumed the role of Chief Executive Officer of the Company.  David B. Henry, previously Non-Executive Chair of the Board, has been appointed to Lead Director.

In 1984, Mr. Tanger joined Stanley K. Tanger as the Company’s fourth employee. At that time, Tanger had seven centers in six states totaling approximately 344,000 square feet. With over 40 years of experience in the outlet industry, Tanger Outlets has grown to include 38 centers in 20 states and Canada, totaling approximately 14.1 million square feet, and hosts more than 180 million visitors annually. The Company has created jobs for more than 40,000 people across the U.S. and Canada.

Previously, Mr. Tanger was a Trustee of the International Council of Shopping Centers (ICSC), a Director of The Fresh Market, a member of the Real Estate Roundtable and a Director and Member of the Executive Committee of the National Association of Real Estate Investment Trusts (NAREIT). Mr. Tanger received the Lifetime Excalibur Award from the American Cancer Society in 1996 for his efforts in the fight against breast cancer, which continue today. In April 2011, Mr. Tanger received the UJA-Federation Award of Excellence and in May 2012, The American Apparel & Footwear Association awarded him the Excellence in Retail Award.

Mr. Tanger has received numerous awards recognizing the highest level of civilian contribution to several states, including North Carolina’s Order of the Long Leaf Pine, The Order of the Palmetto from the State of South Carolina and the Commodores Award in the State of Ohio. In 2013, Mr. Tanger became the named donor for the Steven B. Tanger Performing Arts Center in Greensboro, NC. In 2014, Mr. Tanger won the prestigious Ernst & Young Entrepreneur of the Year Award for the Southeast in Retail and Hospitality and was inducted into the North Carolina Business Hall of Fame for his contributions to the state’s business community over the last 44 years. In 2015, Mr. Tanger was inducted into the Outlet Industry Hall of Fame and was the commencement speaker for the UNC Kenan-Flagler School of Business graduation in 2016.

“I am very proud of what our team accomplished at Tanger Outlets during my 36 years on the management team, including 12 years as CEO.  I look forward to continuing to provide ongoing guidance and support as Executive Chair of the Board.  Since Stephen joined us last April, he has proven to be an invaluable leader and will take our Company to its next stage of our growth,” said Mr. Tanger. “With his extensive experience and successful industry track record, I believe he will be able to help Tanger navigate the ever-evolving retail landscape and position us for success for many years to come.”

“I am honored to assume the role of Chief Executive Officer of Tanger Outlets during this important and transformative time,” said Mr. Yalof. “While 2020 brought unprecedented challenges, our outlook is improving.   We are curating new ways to serve our customers in a safe, secure manner to grow our business for the long-term.”

Mr. Yalof joined Tanger Outlets as President and Chief Operating Officer in April 2020. Prior to Tanger, he served as Chief Executive Officer of Simon Premium Outlets since 2014. Mr. Yalof has over 20 year of experience with retailers, including his tenure in leadership roles at Ralph Lauren Corporation and The Gap, Inc.

About Tanger Factory Outlet Centers, Inc.

Tanger Factory Outlet Centers, Inc. (NYSE: SKT) is a leading operator of open-air upscale outlet shopping centers that owns, or has an ownership interest in, a portfolio of 38 centers. Tanger’s operating properties are located in 20 states and in Canada, totaling approximately 14.1 million square feet, leased to over 2,700 stores operated by more than 500 different brand name companies. The Company has more than 40 years of experience in the outlet industry and is a publicly-traded REIT. For more information on Tanger Outlet Centers, call 1-800-4TANGER or visit the Company’s website at www.tangeroutlets.com.  

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/steven-b-tanger-transitions-from-ceo-to-executive-chair-of-board-of-directors-301200548.html

SOURCE Tanger Factory Outlet Centers, Inc.

NEWARK, N.J., Jan. 5, 2021 /PRNewswire/ — IDT Corporation (NYSE: IDT), a global provider of fintech, cloud communications and traditional communications services, today unveiled a refreshed logo for BOSS Revolution, its flagship consumer service. 

“The new Boss Revolution logo has been updated to capture the evolution of our brand while reflecting our abiding commitment to provide immigrant communities with innovative services that keep them close to friends and family,” said Jessica Poverene, EVP Marketing for BOSS Revolution. 

“The previous logo was introduced in 2008 when BOSS Revolution was solely an affordable international long-distance service distributed through our Boss Revolution retailer network,” Poverene added. 

“Since then, we’ve continuously listened to our customers and have developed additional services and features to meet their needs,” she said.  “Today’s BOSS Revolution offers a robust array of services that make it more convenient than ever to ‘connect, support and share’ with family and friends back home through our popular BOSS Revolution Calling and BOSS Revolution Money apps, our website and kiosks, and our neighborhood BOSS Revolution retailers.”

The BOSS Revolution service now offers:

• Ultra-clear international calls to over 200 countries via low per minute rates and affordable unlimited plans.
• Mobile top-up for prepaid mobile phones of family and friends in 90+ countries with more than 150 carriers around the globe including Tigo, Claro, Cubacel, MTN, Orange, Airtel, Natcom, Flow, Digicel and Glo.
• Money transfer through the interconnected BOSS Revolution Money app, website and authorized BOSS Revolution Money retailers, allowing customers to send money to friends and family in any one of 59 popular destination countries.
• Free calls to other BOSS Revolution app users worldwide when both the caller and recipient use data or Wi-Fi connections.
• Free and fast messaging to any other BOSS Revolution app user. Chat one-on-one or in groups and share pictures, stickers, videos, voice messages and more.
• Free local news, radio, weather and trending movies, music and trending Twitter from around the world.
• Free balance sharing in the BOSS Revolution app. Balance sharing makes it easy to let friends and family get in on fun.

“Our new logo represents all of these great features backed by our dedication to outstanding customer service and continued innovation,” added Poverene.  “The one constant over the years has been our dedication to developing new BOSS Revolution services to help our customers stay close with their families and friends no matter where they are.”

BOSS Revolution customers can use cash at any one of BOSS Revolution’s 35,000+ retailers nationwide. Find the retailer nearest to you here.

The highly rated BOSS Revolution Calling and the BOSS Revolution Money apps are available free on Google Play and in the App Store. 

New BOSS Revolution Calling app customers in the U.S. and Canada get $2 FREE credit.  BOSS Revolution Money customers’ first money transfer up to $300 is free. Just activate the apps anytime in 2021.

About IDT Corporation:

IDT Corporation
 (NYSE: IDT) is a global provider of fintech, cloud and traditional communications services.  We make it easy for families to communicate and support each other across international borders. We also enable businesses to transact and communicate with their customers with enhanced intelligence and insight.

Our BOSS Revolution branded money transfer and international calling services make sending money and speaking with friends and family around the world convenient and reliable.  National Retail Solutions‘ (NRS) point-of-sale retail network enables independent retailers to operate and process transactions more effectively while providing advertisers and consumer marketers with unprecedented reach into underserved consumer markets.  net2phone‘s unified communications as a service solution provides businesses with intelligently integrated cloud communications and collaboration tools across channels and devices. Our IDT Carrier Services and IDT Express wholesale offerings enable communications companies to provision and manage international voice and SMS services.

 

 

 

 

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/boss-revolution-says-hello-to-a-new-logo-301200564.html

SOURCE IDT Corporation